CURATIVE EFFECT EVALUATION OF INTRAPERITONEAL HYPERTHERMIC PERFUSION CHEMOTHERAPY COMBINED WITH APATINIB FOR MALIGNANT ASCITES

This study aims to retrospectively evaluate the curative effect of intraperitoneal hyperthermic perfusion chemotherapy (IHPC) combined with apatinib for malignant ascites of advanced tumours. Twenty peritoneal tumour metastasis patients with ascites were treated with IHPC combined with apatinib. Apatinib was administered at 850 mg daily for four weeks as one cycle. IHPC was applied once a week, for four weeks as a course of treatment. After the initial treatment course of four weeks, indicators of its short-term effect, that is, changes in serum tumour markers CEA, CA125 and CA19-9, as well as ascites volume and scores of Karnofsky performance status (KPS) before and after the treatment, were evaluated. Rezumat Acest studiu și CA19-9, precum și volumul ascitei și scorurile statusului de performanță Karnofsky (KPS).

[1]  Byrne Lee,et al.  Review of Regional Therapies for Gastric Cancer with Peritoneal Metastases , 2022, Cancers.

[2]  I. Radu.  SILK FIBROIN NANOPARTICLES REVEAL EFFICIENT DELIVERY OF 5-FU IN A HT-29 COLORECTAL ADENOCARCINOMA MODEL IN VITRO , 2021, FARMACIA.

[3]  L. Shen,et al.  Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites , 2021, The Journal of international medical research.

[4]  Chengzhen Li,et al.  Efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of malignant ascites , 2020, World Journal of Surgical Oncology.

[5]  R. Berri,et al.  Management of Peritoneal Malignancies , 2019, Textbook of Gastrointestinal Oncology.

[6]  C. Lu,et al.  Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal malignancy: preliminary results of a multi-disciplinary teamwork model in Asia , 2018, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[7]  Yan Li,et al.  Milky spots: omental functional units and hotbeds for peritoneal cancer metastasis , 2016, Tumor Biology.

[8]  Ying Cheng,et al.  Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  N. Colombo,et al.  A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. , 2012, Gynecologic oncology.

[10]  X. Qin,et al.  Hyperthermic intraperitoneal chemotherapy for gastric and colorectal cancer in Mainland China. , 2011, World journal of gastroenterology.

[11]  C. Bokemeyer,et al.  Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? , 2009, The oncologist.

[12]  J. Shih,et al.  Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma , 2008, European Respiratory Journal.

[13]  C. Bokemeyer,et al.  The Local Cytokine and Chemokine Milieu within Malignant Effusions , 2008, Tumor Biology.

[14]  M. Dimopoulos,et al.  Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. , 2008, Gynecologic oncology.

[15]  G. Becker,et al.  Malignant ascites: systematic review and guideline for treatment. , 2006, European journal of cancer.

[16]  S. Kassim,et al.  Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. , 2004, Clinical biochemistry.

[17]  A. van Dalen,et al.  Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma. , 2004, Anticancer research.

[18]  Yu-lan Liu,et al.  Elevation of serum and ascites cancer antigen 125 levels in patients with liver cirrhosis , 2003, Journal of gastroenterology and hepatology.

[19]  G. Jayson,et al.  The current and future management of malignant ascites. , 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).

[20]  C. Marino,et al.  Malignant ascites: new concepts in pathophysiology, diagnosis, and management. , 2001, Archives of internal medicine.

[21]  Y. Yamamoto,et al.  Hot spots observed on pulmonary perfusion imaging: a case report. , 1999, Journal of Nuclear Medicine Technology.